Drug Trial Radar · NCT06793826
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
713
Actual
Start
Jan 17, 2025
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objectives: To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications
Conditions
- Hepatitis B
- Haemophilus Influenzae Type b Immunisation
Interventions
DTaP-IPV-Hep B-PRP-T combined vaccineBiological
prefilled syringe injection intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting immediate adverse events/adverse drug reactions (AEs/ADRs)Time frame: Within 30 minutes post-vaccination
- Number of participants reporting serious adverse events / adverse drug reactions (SAEs / SADRs)Time frame: Up to 43 days post-vaccination
- Number of participants reporting solicited injection site and systemic reactionsTime frame: Up to 7 days post-vaccination
- Number of participants reporting unsolicited non-serious AEs/ADRsTime frame: Up to 28 days post-vaccination
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 002
Cheonan, South Korea
Investigational Site Number : 001
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.